Abstract
Statins are widely used to decrease cholesterol synthesis and reduce cardiovascular events and mortality. Recently, it has been recognized that mobilization of progenitor cells plays an important role in the cardioprotection of statins. Circulating progenitor cell activity, indicated by CD34+ counts, is positively associated with statin therapy in a large cohort [1]. Statin therapy can directly increase circulating progenitor cells in patients with cardiovascular diseases [2]. Moreover, after acute myocardial infarction, the spontaneous mobilization of bone marrow progenitor cells is augmented in patients on statin therapy, and this contributes to a favorable cardiac remodeling [3,4].
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
